Since my PER fiasko I tend to think the preventive arm had too few participants. Would appreciate if someone can ease my mind here….Would it make Sense to increase dosing for therapeutic case and see if there is more than „just“ activity? The company is not that rich and moving to phase 3 would be too expensive maybe. Hence, i assume the Share Price Situation.
Ann: Successful Phase 2 clinical trial of ISLA-101, page-77
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
16.5¢ |
Change
-0.020(10.8%) |
Mkt cap ! $38.95M | |||
| Open | High | Low | Value | Volume |
| 18.5¢ | 18.5¢ | 16.5¢ | $31.63K | 182.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 69059 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.5¢ | 85485 | 1 |
View Market Depth
| Last trade - 16.10pm 16/06/2025 (20 minute delay) ? |
| ILA (ASX) Chart |